Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. - Liao PW; Ko BS; Su YC; Chao WT; Teng CJ (Cancer medicine, 2026)